Physician profile
Xujun Wu
NPI 1235117425
$1,426.84
in general payments reported to CMS, 2019-2025
15 companies · $357 in 2025
The $357 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $116 · 2020: $14.00 · 2021: $125 · 2022: $122 · 2023: $503 · 2024: $189 · 2025: $357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,029 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,029.11 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $569.50 | 2022-2025 | Skyrizi, Rinvoq, Linzess |
| Celgene Corporation | $209.46 | 2022-2024 | Zeposia |
| Janssen Biotech, INC. | $128.63 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $78.81 | 2019-2025 | Eohilia |
| Ferring Pharmaceuticals INC. | $77.41 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $72.96 | 2021-2023 | Dificid |
| Lilly USA, LLC | $59.41 | 2025 | Omvoh |
| Boston Scientific Corporation | $51.73 | 2019-2023 | Resolution Clip |
| Allergan, INC. | $36.60 | 2019 | |
| Pfizer INC. | $33.76 | 2021-2022 | |
| Genzyme Corporation | $26.84 | 2025 | |
| Olympus America INC. | $26.35 | 2023 | Endoclot Phs |
| Ethicon US, LLC | $20.26 | 2019 | |
| Csl Behring | $20.00 | 2024 | Kcentra |
| Madrigal Pharmaceuticals | $15.12 | 2025 | Rezdiffra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xujun Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.